文献速递呼吸危重症与机械通气

胸廓限制性疾病患者无创通气医保覆盖优化:多学会技术专家组报告

Optimal NIV Medicare Access Promotion: Patients With Thoracic Restrictive Disorders: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society.
PubMed 文献 · Chest · 2021-07-30

美国胸科医师学会等四学会技术专家组针对胸廓限制性疾病患者无创通气(NIV)的现有医保覆盖标准提出优化建议,指出当前存在NIV启动延迟、非进展性神经肌肉疾病覆盖不足及家庭机械通气(HMV)政策不明确等障碍,并给出5项关键推荐以促进早期NIV和适时升级HMV。

要点

  • 推荐即使FVC轻度降低,症状也应作为启动双水平正压通气的原因。
  • CO2监测可扩展至经皮、呼气末或静脉血气等替代指标。
  • 诊断类别应纳入膈神经损伤和中枢驱动障碍。

核心结论

  • 现有NIV覆盖标准未认可胸廓限制性疾病早期NIV获益及日间支持需求。
  • 采纳推荐可为合适患者及时提供合适设备。

研究设计与样本

  • 美国胸科医师学会、美国呼吸治疗协会、美国睡眠医学会和美国胸科学会技术专家组工作报告。

主要发现

  • 当前主要覆盖障碍包括NIV实施延迟、许多非进展性神经肌肉疾病缺乏覆盖、胸廓限制性疾病HMV支持政策指征不明确。

关键数值与推荐

  • 症状应作为FVC轻度降低时启动双水平正压通气的原因。
  • CO2测量可扩展至经皮、呼气末或静脉血气等替代指标。
  • 诊断类别扩展至膈神经损伤和中枢驱动障碍。
  • 肺活量<30%或严重日间呼吸症状时允许双水平正压通气设备升级为HMV。
  • 患者依赖呼吸机且每日使用>18小时应提供额外HMV。

临床怎么用

  • 对胸廓限制性疾病患者,即使FVC轻度降低,若有症状即可考虑启动NIV。
  • 可用经皮、呼气末或静脉血气替代动脉血CO2监测。
  • 肺活量<30%或严重日间症状时,将双水平设备升级为HMV。
  • 呼吸机依赖每日>18小时者应提供额外HMV支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The existing coverage criteria for noninvasive ventilation (NIV) do not recognize the benefits of early initiation of NIV for those with thoracic restrictive disorders and do not address the unique needs for daytime support as the patients progress to ventilator dependence. This document summarizes the work of the thoracic restrictive disorder Technical Expert Panel working group. The most pressing current coverage barriers identified were: (1) delays in implementing NIV treatment; (2) lack of coverage for many nonprogressive neuromuscular diseases; and (3) lack of clear policy indications for home mechanical ventilation (HMV) support in thoracic restrictive disorders. To best address these issues, we make the following key recommendations: (1) given the need to encourage early initiation of NIV with bilevel positive airway pressure devices, we recommend that symptoms be considered as a reason to initiate therapy even at mildly reduced FVCs; (2) broaden CO2 measurements to include surrogates such as transcutaneous, end-tidal, or venous blood gas; (3) expand the diagnostic category to include phrenic nerve injuries and disorders of central drive; (4) allow a bilevel positive airway pressure device to be advanced to an HMV when the vital capacity is < 30% or to address severe daytime respiratory symptoms; and (5) provide additional HMV when the patient is ventilator dependent with use > 18 h per day. Adoption of these proposed recommendations would result in the right device, at the right time, for the right type of patients with thoracic restrictive disorders.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Wolfe LF, Benditt JO, Aboussouan L, et al. Optimal NIV Medicare Access Promotion: Patients With Thoracic Restrictive Disorders: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. Chest. 2021. PMID: 34339688. doi:10.1016/j.chest.2021.05.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。